GY037: A Phase III study of induction pembrolizumab and chemotherapy followed by chemoradiation and pembrolizumab versus chemoradiation and pembrolizumab both followed by pembrolizumab for high risk locally advanced cervical cancer (NCT04158141)
GY035: A Randomized Phase III Trial of Carboplatin, Paclitaxel, and Pembrolizumab versus Carboplatin, Paclitaxel, and Bevacizumab versus Carboplatin, Paclitaxel, Pembrolizumab and Bevacizumab in the Treatment of PMMR, TP53 Mutated Advanced or Recurrent Endometrial Cancer (NCT07198074)
GY036: A Phase III Trial of One vs. Two Years of Maintenance Olaparib, with or without Bevacizumab, in Patients with BRCA1/2 Mutated or Homologous Recombination Deficient (HRD+) Ovarian Cancer Following Response to First Line Platinum-Based Chemotherapy (NCT#06580314)
GY032: A PHASE II STUDY OF TAILORED ADJUVANT THERAPY IN POLE-MUTATED AND p53-WILDTYPE/NSMP EARLY-STAGE ENDOMETRIAL CANCER (RAINBO BLUE & TAPER)
GOG3115/M25-231
A Single-Arm, Phase 2 Study of Neoadjuvant Carboplatin and Mirvetuximab Soravtansine in Subjects with FRα-Expressing Advanced-Stage Serous Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer
Read More
